For the first time, the result provides in vivo genetic evidence demonstrating that the endogenous cardiomyocyte Smad4-dependent TGF-β pathway protects heart from cardiac hypertrophy and fibrosis. The gene discussed is SMAD4; the disease is cardiac hypertrophy.